Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ARGX stock, giving a Buy rating on August 26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Smith has given his Buy rating due to a combination of factors surrounding the recent positive developments for Argenx Se’s Vyvgart. The company announced successful Phase 3 trial results for Vyvgart in treating seronegative myasthenia gravis (MG), which met its primary endpoint with high statistical significance and maintained a favorable safety profile. This success is expected to lead to a label expansion for Vyvgart, potentially increasing its target market by approximately 11,000 additional patients.
Moreover, the expansion into new MG subtypes could significantly enhance Vyvgart’s market presence and drive long-term demand, as there are currently limited approved therapies for these conditions. Argenx’s strategic trial design and execution are expected to further distinguish Vyvgart in the competitive MG landscape. Additionally, Argenx is advancing Vyvgart for other autoimmune indications, which could further bolster its market potential and revenue growth.
According to TipRanks, Smith is a top 100 analyst with an average return of 42.3% and a 54.62% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Sagimet Biosciences, Inc. Class A, and MoonLake Immunotherapeutics.
In another report released on August 26, Piper Sandler also maintained a Buy rating on the stock with a $820.00 price target.